Less frequently, patients may present with AA amyloidosis without any preceding clinical complaints or detected acute phase elevation, so-called “phenotype 2.” Various biomarkers are generally evaluated during follow-ups in FMF patients, mainly ESR and CRP, to monitor disease activity and treatment adequacy. Here, ESR1 is linked to familial Mediterranean fever.